Chronic hepa==s B (CHB) remains a global healthcare challenge, complicated by the development of cirrhosis and hepatocellular carcinoma, accoun=ng for approximately 600,000 deaths per year. Hepa==s B is a DNA virus, which u=lises a covalently closed circular (ccc) DNA to act as a transcrip=onal template for the virus. The persistence of cccDNA in the nucleus of infected hepatocytes accounts for HBV chronicity. Quan=ta=ve hepa==s B surface an=gen (qHBsAg) acts as a surrogate for the level of cccDNA and therefore may provide useful informa=on around treatment response and viral immune control. Current an=viral therapies are limited in their ability to achieve HBsAg loss, which is considered the 'gold-standard' treatment endpoint. This ar=cle focuses on the unmet needs in CHB today; a be`er defini=on of disease phase, the =ming of therapeu=c interven=on, op=mising treatment strategies with current therapies and the development of novel agents; all with HBsAg loss as the therapeu=c goal.
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Key points
CHB is a complex dynamic disease requiring specialist input and management CHB pa=ents, both treated and untreated, require long-term monitoring
The u=lity of qHBsAg can enhance disease categorisa=on and guide management decisions
The limited efficacy of current an=viral therapies (PegIFN and NUCs) warrants the development of new therapeu=c approaches Future therapies should be individualised with the ul=mate goal being eradica=on of virus.
IntroducEon
The emergence of directly ac=ng an=virals for the treatment of hepa==s C virus (HCV) represents a realis=c opportunity to eliminate hepa==s C; however, the lack of similar agents for the treatment of chronic hepa==s B virus (CHB) will mean renewed focus on the treatment and management of CHB in the coming years.
Despite the availability of a preventa=ve vaccine for almost 40 years, the WHO es=mates that more than 400 million people worldwide are chronically infected with hepa==s B virus (HBV). An es=mated 600,000 deaths per year are a`ributed to cirrhosis and hepatocellular carcinoma (HCC) complica=ng CHB. 1 In the UK, according to the Na=onal Ins=tute of Health and Care Excellence (NICE), as many as 500,000 people may have chronic infec=on, with most disease seen among migrants who acquired their infec=on in childhood from their na=ve country. 2 HBV is a small enveloped DNA virus which infects hepatocytes. Within the hepatocyte the HBV genome is converted to a covalently closed circular (ccc) DNA that serves as a template for transcrip=on of all the viral proteins. 3 cccDNA plays a key role in the viral life cycle and its persistence in the nucleus of infected hepatocytes is the basis of HBV chronicity. Hepa==s B surface an=gen (HBsAg), the hallmark of CHB, is thought to act as a surrogate for the level of cccDNA and thus recent studies have focused on the u=lity of quan=ta=ve HBsAg (qHBsAg) to profile disease and assess treatment response; with HBsAg loss considered the 'gold-standard' treatment endpoint. 4 Current an=viral therapies include pegylated interferon (PegIFN) and nucleos(t)ide analogues (NUCs), both of which offer limited efficacy in achieving HBsAg loss, therefore life-long treatment with viral suppression represents the standard of care in the majority of pa=ents. This underlines the challenges we face in the management of CHB and the need for novel treatment strategies to mirror the recent advances in the HCV treatment landscape. 5 
Natural history of HBV Diagnosis
The detec=on of HBsAg in the serum on two occasions 6 months apart is diagnos=c of CHB. However, HBsAg posi=vity should trigger a broader panel of inves=ga=ons, including viral serology coupled with biochemical tests, to profile the disease and facilitate management ( Table 1) . Quan=ta=ve HBV DNA and the liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), are key markers of disease, reflec=ng replica=ng virus and liver inflamma=on/injury, respec=vely. In addi=on, a full chronic liver disease screen and baseline imaging should be performed for formal disease assessment ( Table 1) . Table 1 .
Laboratory tests for diagnosis and monitoring in the treated and nontreated pa=ent with HBV infec=on.
Disease phase
CHB is a dynamic disease characterised by four dis=nct disease phases or clinical categorisa=ons, which are used to define disease state and determine management decisions (Fig 1 and 2 ).
Fig 1.
Characteris=cs of disease phase in CHB with corresponding schema=c. ALT = alanine aminotransferase; CHB = chronic hepa==s B virus; HBeAg = hepa==s B e an=gen; HBeAb = hepa==s B e an=body; HBsAg = hepa==s B surface an=gen; HBV DNA = hepa==s B viral load.
Fig 2.
Algorithm for disease assessment and monitoring in each disease phase of CHB. ALT = alanine aminotransferase; CHB = chronic hepa==s B virus; HBeAg = hepa==s B e an=gen; HBsAg = hepa==s B surface an=gen; HBV = hepa==s B virus; TE = transient elastography.
Immune tolerance is associated with perinatal infec=on or infec=on in early childhood and thus this phase is synonymous with disease in children or young people. The hallmarks of immune tolerance are hepa==s B e an=gen (HBeAg) posi=vity, high levels of HBV DNA and normal serum ALT with minimal or no liver fibrosis on biopsy. This phase of disease is believed to last from a few years to several decades. 6 The immune ac=ve (or immune clearance) phase is characterised by the presence of HBeAg,
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In this window In a new window fluctua=ng levels of HBV DNA (usually >20,000 IU/ml) and elevated serum ALT, reflec=ng immunemediated liver injury. HBeAg seroconversion during this phase may result in immune control of the virus omen referred to as the 'inac=ve carrier' (IC) phase. Characterised by the loss of HBeAg, pa=ents are an=-HBe posi=ve with normal serum ALT and HBV DNA <2,000 IU/ml. This phase of disease represents the host's ability to control the virus; therefore transi=on from the immune ac=ve to the immune control phase is unpredictable and not an inevitable sequence of events. 7 A propor=on of inac=ve carriers may develop disease reac=va=on with elevated HBV DNA levels and fluctua=ons in the serum ALT. Driven by muta=ons in the pre-core or core promoter regions of the virus (immune escape), HBeAg is not secreted and this disease phase is referred to as HBeAgnega=ve CHB. 8 Similarly, pa=ents may progress to HBeAg-nega=ve CHB from the immune ac=ve disease phase following HBeAg seroconversion, if they fail to establish immune control of the virus exemplified by low levels of HBV DNA (<2,000 IU/ml) and normal liver enzymes (Fig 1 and 2) .
Novel insights into disease phase
Current prac=ce stra=fies disease phase based exclusively on HBV DNA and ALT levels, however, there is a growing debate on the accuracy of these clinical parameters to reflect disease phase immunologically. [9] [10] [11] The u=lity of qHBsAg, an indirect measure of transcrip=onal cccDNA, may enhance disease stra=fica=on (Fig 1) . Cross-sec=onal studies demonstrate a varia=on in qHBsAg levels during the natural history of CHB and may enhance management decisions. Highest in immune tolerant disease, recent studies have shown an inverse correla=on between qHBsAg level and liver fibrosis in HBeAg-posi=ve disease. 12 The lowest levels of qHBsAg are observed in HBeAgnega=ve ICs, where low qHBsAg levels reflect immune control and importantly, may help to risk stra=fy pa=ents for disease progression and the development of HCC. 13 
Treatment and monitoring
Through the inhibi=on of the HBV reverse transcriptase, NUCs (Table 2) provide on-treatment suppression of HBV replica=on. While offering potent viral suppression with a high gene=c barrier to resistance, these drugs do not achieve cure owing to the persistence of cccDNA in infected hepatocytes. Conversely, PegIFN can result in virus clearance, but its efficacy is limited to a small propor=on of pa=ents and it can be associated with systemic side effects. 5 Table 2 .
Comparison of an=viral therapies for CHB with indica=on of stopping rules for PegIFN use.
The treatment sequence
NICE and interna=onal guidelines differ in their recommenda=ons for first-line therapies. NICE recommends PegIFN as first-line treatment in adults with HBeAg-posi=ve or nega=ve compensated liver disease, with NUCs (tenofovir/entecavir) offered as a second line in those with a subop=mal response to PegIFN (Table 2 ). Both the European Associa=on for the Study of the Liver (EASL) and the American Associa=on for the Study of Liver Diseases (AASLD) offer more flexibility in treatment selec=on, with the choice of first-line agent being lem to physician discre=on. 14, 15 Prior to the ini=a=on of any first-line therapy (PegIFN/NUC), specific laboratory tests should be performed to ensure there is no contraindica=on to the selected therapy and provide baseline measurements for on-treatment monitoring (Table 1) .
Pegylated interferon
Advantages of PegIFN include a finite treatment course and the absence of an=viral resistance. Owing to its immunomodulatory ac=vity, off-treatment immune control is achievable. Approximately 30% of HBeAg-posi=ve pa=ents have a favourable response to PegIFN with sustained HBeAg seroconversion, with a propor=on of these pa=ents going on to achieve HBsAg loss, the closest outcome to a clinical cure. 16 Importantly, PegIFN also has a role in HBeAgnega=ve disease, where a sustained virologic response (HBV DNA <2,000 IU/ml) is seen in up to 40% of pa=ents and HBsAg loss reported in approximately 12% at 5 years post treatment. 17 Recently described early stopping rules (Table 2) , based primarily on HBsAg decline at week 12 (or 24) of therapy, can guide physicians in determining where treatment can be stopped early owing to subop=mal response; thus avoiding the poten=al undesirable effects associated with a fulltreatment course. This strategy would allow an early switch to NUC therapy, providing an individualised approach to CHB treatment. 5, 16, 17 
Nucleos(t)ide analogues
Tenofovir and entecavir represent third-genera=on NUCs and may be offered as a first-line therapy in CHB, or following subop=mal response to PegIFN. 5 Associated with less systemic side effects, monitoring of pa=ents on NUC therapy is mandated to assess response and detect poten=al adverse events associated with long-term therapy (Table 1) 
Monitoring the untreated paEent
Monitoring of non-treatment candidates is mandated to detect disease progression and determine the =ming of any therapeu=c interven=on (Fig 2) . The frequency of monitoring is debated, with a delicate balance between overzealous monitoring and the minimum frequency of follow up without puung pa=ents at risk. The op=mum monitoring of immune-tolerant pa=ents remains unclear; while three-monthly laboratory tests are likely to capture fluctua=ons in biochemical ac=vity or viral load, it may take many years for progression of disease from the tolerant to the immune-ac=ve phase. Recent work in ICs has demonstrated how qHBsAg can enhance monitoring and iden=fy those at greatest risk of disease progression (reac=va=on) or the development of HCC. In this disease phase, low levels of qHBsAg define a 'low-risk' IC profile where monitoring frequency can be reduced. 12, 13 Similarly, integra=ng qHBsAg into disease profile to define immune tolerance could poten=ally streamline the frequency of monitoring in this group.
The cirrhoEc paEent
HBV-related decompensated cirrhosis is an absolute indica=on for NUC therapy, which can adequately suppress viral replica=on, poten=ally reverse fibrosis, prevent liver transplanta=on and even the development of HCC. 18 Lifelong use of NUCs in cirrho=c pa=ents is the standard of care to prevent complica=ons of CHB. Conversely, PegIFN is an absolute contraindica=on in decompensated disease. In addi=on to the rou=ne laboratory monitoring, similar to that in the non-cirrho=c pa=ent, cirrho=c pa=ents should undergo screening for HCC with six-monthly surveillance ultrasound scan (+/-) α-fetoprotein (AFP) ( Table 1) .
Novel treatment strategies in CHB
Novel strategies to maximise the efficacy of currently available treatments, including the combina=on of these agents or their use in sequence, are currently under inves=ga=on. 20, 21 Eradica=on of the virus is the ideal therapy goal. Novel agents with promise include viral entry inhibitors, targets against cccDNA forma=on and degrada=on. In addi=on, strategies to enhance the host immune response against HBV and the role of therapeu=c vaccina=on are under inves=ga=on. The majority of these strategies are at a pre-clinical stage and their poten=al therapeu=c impact remains unknown. 22, 23 Furthermore, these strategies are likely to be combined with NUCs and/or PegIFN in the short term, therefore the therapies used in today's clinic are likely to cons=tute a central component of treatment strategies for the foreseeable future. 24 
Summary
CHB remains a major global healthcare challenge, accoun=ng for more than 50% of the cases of primary liver cancer worldwide. The complexity of CHB and its dynamic nature necessitate specialist input to make appropriate treatment and management decisions. However, current therapies remain subop=mal and fail to achieve HBsAg loss, the 'gold-standard' treatment endpoint, in the majority of pa=ents. In light of the recent advances in HCV treatment, there is a need for similar progress in the HBV therapy field to make eradica=on of the virus a realis=c prospect. In order to achieve this goal, novel agents must be developed in addi=on to op=mising the use of currently available agents. The central tenet, however, remains a be`er understanding of disease phase and =ming of therapeu=c interven=on.
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